Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Herpes Labialis
Interventions: Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference), Placebo cream; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years and older
Enrollment: 4,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With FGFR3 Mutation or Fusion, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation
Interventions: BGJ398; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Depression, Anxiety, Major Depressive Disorder
Interventions: CYB003, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Cancer, Non-Small Cell Lung Cancer
Interventions: MKC-1, pemetrexed; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Seattle, Washington + 1 more

Conditions: Cleft Lip, Cleft Palate
Interventions: Folic acid: 4 mg versus 0.4 mg per day; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Malocclusion
Interventions: Fixed Orthodontic Appliance Treatment, OrthoPulse™, Non-Functional OrthoPulse™; Other · Device
Lead sponsor: Biolux Research Holdings, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Suwanee, Georgia

Conditions: Cleft Lip, Congenital Nose Malformation, Deformity, Nose Deformities, Acquired
Interventions: Cleft Lip/Nose Repair without PSIO, Presurgical Infant Orthopedic Therapy; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Months to 1 Month
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breakthrough Bleeding
Interventions: Birth control pills; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2004
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Corneal Ulcer, Eye Infections, Fungal
Interventions: Voriconazole, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Peripheral Neuropathy, Trigeminal Neuralgia
Interventions: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes; Biological
Lead sponsor: The Foundation for Orthopaedics and Regenerative Medicine; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Bruxism, Sleep-Related
Interventions: Not listed
Lead sponsor: Otis Dental, LLC; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Embolism, Thrombosis
Interventions: Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions: PU-H71; Drug
Lead sponsor: Samus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Larkspur, California • Los Angeles, California • Houston, Texas

Conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions: Canagliflozin (JNJ-28431754), Sitagliptin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more

Conditions: Crohn Disease
Interventions: Ozanimod; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Garden Grove, California • Los Angeles, California • Sacramento, California + 15 more

Conditions: Urethral Stricture, Male
Interventions: Standard Buccal Harvest, Basic buccal procedure + Long acting local, Basic buccal procedure + Buccal block; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: San Francisco, California • Washington D.C., District of Columbia

Conditions: Head and Neck Cancer
Interventions: carboplatin, cisplatin-e therapeutic implant, paclitaxel; Drug
Lead sponsor: Matrix Pharmaceutical; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 4
States / cities: Phoenix, Arizona • Tucson, Arizona • Evanston, Illinois + 1 more

Conditions: Sleep Apnea, Obstructive
Interventions: Oral appliance, BluePro oral appliance; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus, Periodontal Disease
Interventions: Periodontal Scaling and root planing; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
Interventions: CC-223; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more

Conditions: Tooth Loss
Interventions: Particulate bone graft, Autogenous dental pulp tissue, Resorbable collagen membrane, Suture; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clostridium Difficile, Spinal Cord Injury
Interventions: Fidaxomicin 200 mg, Placebo, Vancomycin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Oral Triamcinalone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Insomnia
Interventions: zolpidem tartrate; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer

Oral Cleft Prevention Program

Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time

Fabrication of Sequential Naso-Alveolar Molding Appliances in the Treatment of Cleft Lip/Nose Deformities

Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

Safety of Cultured Allogeneic Adult Umbilical Cordor Placental Derived Stem Cells Exosomes for Trigeminal Neuralgia

A Sensor-enhanced Mouth Guard to Quantitatively Measure Bite Compression Forces.

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Peri-operative Oral Pain Control Following Buccal Graft Urethroplasty

Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer

Characterizing Upper Airway Collapse to Guide Patient Selection for Oral Appliance Therapy for Obstructive Sleep Apnea

The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 Diabetes

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

The Use of Dental Pulp Tissue as an Autogenous Graft for Ridge Augmentation

Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury

A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer

Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo